Drug Treatment Center

Rockwell Medical Technologies, Inc. Announces Patient Enrollment - MSN MoneyCentral
WIXOM, Mich., April 29, 2009 (GLOBE NEWSWIRE) — Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney

FDA Grants Orphan Drug Designation to Oncophage for the Treatment of - Businesswire.com
NEW YORK–( BUSINESS WIRE )–Antigenics Inc. (NASDAQ: AGEN) today announced that Oncophage ® (vitespen) has been granted orphan drug status for the treatment of glioma (brain cancer) by the US Food and Drug Administration (FDA). In March, the

Rockwell Medical Technologies, Inc. Announces Patient Enrollment - MSN MoneyCentral
WIXOM, Mich., April 29, 2009 (GLOBE NEWSWIRE) — Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney

FDA Grants Orphan Drug Designation to Oncophage for the Treatment of - Businesswire.com
NEW YORK–( BUSINESS WIRE )–Antigenics Inc. (NASDAQ: AGEN) today announced that Oncophage ® (vitespen) has been granted orphan drug status for the treatment of glioma (brain cancer) by the US Food and Drug Administration (FDA). In March, the

This entry was posted on Wednesday, April 29th, 2009 at 1:42 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.